menu

Q&AD: Addressing Challenges in Alzheimer’s Disease, From Early Identification to New Treatment Considerations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Q&AD: Addressing Challenges in Alzheimer’s Disease, From Early Identification to New Treatment Considerations

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.

    In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment. Throughout this activity, we will gather questions from clinicians like you who care for patients living with dementia, and then in part two of this series, we will answer some of the questions generated from this first activity.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity. 

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Valerie Siclari, PhD; Megan Ragan
    • Moderator: Jennifer Caudle, DO
    • Faculty Presenter: Brad Dickerson, MD

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty Presenter: Alireza Atri, MD, PhD

    • Researcher: Athira, Alzheon, Biogen, Biohaven, Eisai, Lilly, Vivoryon
    • Consultant/Advisor: AbbVie, Acadia, AZ Therapies, Biogen, Eisai, JOMDD, Lundbeck, Roche/Genentech, Novo Nordisk, and Qynapse

    Faculty Presenter: Sharon J. Sha, MD, MS

    • Researcher: Acadia, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, Novartis
    • Consultant: ExpertConnect, Guidepoint Global, Office Hours
  • Target Audience

    The target audience includes neurologists and others involved in the care of patients with dementia, including other physicians, nurse practitioners, and physician assistants.

  • Learning Objectives

    As a result of participation in this initiative, participants will increase their ability to:

    1. Explain the current understanding of AD biopathology and the new and emerging therapies targeting this pathology
    2. Utilize clinical approaches for early detection of suspected cognitive impairment due to AD
    3. Apply available evidence for patient selection, appropriate use, and care considerations (eg, safety monitoring) for mAb treatment in AD
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Biogen.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

    Provided by Forefront Collaborative.

  • Commercial Support

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.

    In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment. Throughout this activity, we will gather questions from clinicians like you who care for patients living with dementia, and then in part two of this series, we will answer some of the questions generated from this first activity.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity. 

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Valerie Siclari, PhD; Megan Ragan
    • Moderator: Jennifer Caudle, DO
    • Faculty Presenter: Brad Dickerson, MD

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty Presenter: Alireza Atri, MD, PhD

    • Researcher: Athira, Alzheon, Biogen, Biohaven, Eisai, Lilly, Vivoryon
    • Consultant/Advisor: AbbVie, Acadia, AZ Therapies, Biogen, Eisai, JOMDD, Lundbeck, Roche/Genentech, Novo Nordisk, and Qynapse

    Faculty Presenter: Sharon J. Sha, MD, MS

    • Researcher: Acadia, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, Novartis
    • Consultant: ExpertConnect, Guidepoint Global, Office Hours
  • Target Audience

    The target audience includes neurologists and others involved in the care of patients with dementia, including other physicians, nurse practitioners, and physician assistants.

  • Learning Objectives

    As a result of participation in this initiative, participants will increase their ability to:

    1. Explain the current understanding of AD biopathology and the new and emerging therapies targeting this pathology
    2. Utilize clinical approaches for early detection of suspected cognitive impairment due to AD
    3. Apply available evidence for patient selection, appropriate use, and care considerations (eg, safety monitoring) for mAb treatment in AD
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Biogen.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

    Provided by Forefront Collaborative.

  • Commercial Support

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule26 Jun 2022
Webpack App